key: cord-0812506-v6rc5stb
authors: Vousden, N.; Bunch, K.; Morris, E.; Simpson, N.; Gale, C.; O'Brien, P.; Quigley, M.; Brocklehurst, P.; Kurinczuk, J. J.; Knight, M.
title: The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: a national cohort study using the UK Obstetric Surveillance System (UKOSS)
date: 2021-01-05
journal: nan
DOI: 10.1101/2021.01.04.21249195
sha: 9224a390ba2c0a922ab7670008610e7db4890bd6
doc_id: 812506
cord_uid: v6rc5stb

Background: Evidence on risk factors, incidence and impact of SARS-CoV-2 infection in pregnant mothers and their babies has rapidly expanded but there is a lack of population level data to inform accurate incidence rates and unbiased descriptions of characteristics and outcomes. The primary aim of this study was to describe the incidence, characteristics and outcomes of hospitalized pregnant women with symptomatic and asymptomatic SARS-CoV-2 in the UK compared to pregnant women without SARS-CoV-2 in order to inform future clinical guidance and management. Methods and Findings: We conducted a national, prospective cohort study of all hospitalized pregnant women with confirmed SARS-CoV-2 from 1st March 2020 to 31st August 2020 using the UK Obstetric Surveillance System (UKOSS) across all 194 hospitals in the UK with a consultant-led maternity unit. Incidence was estimated using the latest national maternity data. Overall, 1148 hospitalized women had confirmed SARS-CoV-2 in pregnancy, 63% of which were symptomatic. Therefore, the estimated incidence of hospitalization with symptomatic SARS-CoV-2 was 2.0 per 1000 maternities (95% CI 1.9-2.2) and for asymptomatic SARS-CoV-2 was 1.2 per 1000 maternities (95% CI 1.1-1.4). Compared to pregnant women without SARS-CoV-2, women hospitalized with symptomatic SARS-CoV-2 were more likely to be overweight or obese (adjusted OR 1.86, 95% CI 1.39-2.48 and aOR 2.07, 95% CI 1.53-2.29 respectively), to be of Black, Asian or Other minority ethnic group (aOR 6.24, 95% CI 3.93-9.90, aOR 4.36, 95% CI 3.19-5.95 and aOR 12.95, 95% CI 4.93-34.01 respectively), and to have a relevant medical comorbidity (aOR 1.83, 95% CI 1.32-2.54). Compared to pregnant women without SARS-CoV-2, hospitalized pregnant women with symptomatic SARS-CoV-2 were more likely to be admitted to intensive care (aOR 57.67, 95% CI 7.80-426.70) but the absolute risk of poor outcomes was low. Cesarean births and neonatal unit admission were increased regardless of symptom status (symptomatic aOR 2.60, 95% CI 1.97-3.42 and aOR 3.08, 95% CI 1.99-4.77 respectively; asymptomatic aOR 2.02, 95% CI 1.52-2.70 and aOR 1.84, 95% 1.12-3.03 respectively). Iatrogenic preterm births were more common in women with symptomatic SARS-CoV-2 (aOR 11.43, 95% CI 5.07-25.75). The risks of stillbirth or neonatal death were not significantly increased, regardless of symptom status but numbers were small. The limitations of this study include the restriction to women hospitalized with SARS-CoV-2, who may by nature of their admission have been at greater risk of adverse outcome. Conclusions: We have identified factors that increase the risk of symptomatic and asymptomatic SARS-CoV-2 in pregnancy. The increased risks of cesarean and iatrogenic preterm birth provide clear evidence of the indirect impact of SARS-CoV-2 on mothers and maternity care in high income settings. Clinicians can be reassured that the majority of women do not experience severe complications of SARS-CoV-2 in pregnancy and women with mild disease can be discharged to continue their pregnancy safely.

In March 2020 the World Health Organization declared a global pandemic of novel coronavirus 70 infection (SARS-CoV-2) [1] . Evidence about risk factors, incidence and impact of SARS-CoV-2 infection 71 in pregnant mothers and their babies has rapidly expanded and is vital to planning guidance and policy. 72

The World Health Organization's (WHO) living systematic review concluded that SARS-CoV-2 infection 73 was associated with increased risk of admission to intensive care for the mother and increased risk of 74 preterm birth and admission to neonatal care for the infant [2] . Women with pre-existing medical 75 comorbidities, older age, high body mass index (BMI) and women of Black, Asian and minority ethnic 76 groups have been reported to be at increased risk of hospitalization [3] or severe outcome [2] . 77 However, the majority of studies to date are case reports, case series and institutional or registry non-78 population-based cohort studies and there is a lack of population-level data to inform accurate 79 incidence rates and unbiased descriptions of characteristics and outcomes. 80 81 Clinical practice around testing for SARS-CoV-2 among pregnant women in the UK has changed since 82 the start of the pandemic, when predominantly only those with symptoms were tested. Routine 83 screening of all obstetric admissions was recommended by the Royal College of Obstetricians and 84

Gynaecologists (RCOG) on 29 th May 2020 [4] and therefore the UK's obstetric population is unique in 85 that virtually all were tested thereafter, typically at the time of giving birth. The WHO systematic 86 review reported from 11 small observational studies (n=162 women that had universal screening) and 87 suggested that a high proportion of women who tested positive were asymptomatic (74%, 95% CI 88 51%-93%) [2] . Other reports have varied [5, 6] , with between 79% (from a total of 55 women)[7] to 89 100% (from a total of 17 women) [8] of those that tested positive on universal screening being 90 asymptomatic. However, these studies were small and were undertaken in single hospitals or regions. 91 No published studies to date have explored the proportion of symptomatic versus asymptomatic 92 SARS-CoV-2 in pregnancy at the population level since universal screening was introduced. 93 94 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi. org/10.1101 org/10. /2021 The primary aim of this study was to describe the incidence, characteristics and outcomes of 95 hospitalized pregnant women with symptomatic and asymptomatic SARS-CoV-2 in the UK compared 96 to women without SARS-CoV-2, in order to inform ongoing guidance and management. The second 97 aim was to describe characteristics and outcomes in women with symptomatic SARS-CoV-2 compared 98 to those who remained asymptomatic. 99 100 METHODS 101 102 This on-going national, prospective observational cohort study was conducted using the UK Obstetric 103

Surveillance System (UKOSS) [9] . UKOSS is a research platform that was established in 2005 to collect 104 national population-based information about specific severe pregnancy complications. All 194 105 hospitals in the UK with a consultant-led maternity unit participate, and thus the mechanism to collect 106 comprehensive information about women hospitalized with SARS-CoV-2 in pregnancy was already in 107 place at the start of the pandemic. Nominated reporting clinicians were asked to notify all pregnant 108 women admitted to their hospital with confirmed SARS-CoV-2. The process was enabled by research 109 midwives and nurses from the UK's National Institute of Health Research Clinical Research Network 110 following the study's adoption as an urgent public health priority study [10] . To check for 111 completeness, a monthly reporting email was sent in addition to receipt of live reports, and zero 112 reports were confirmed. Following notification of a case, clinicians completed an electronic data 113 collection form containing anonymized details of women's demographics, management and birth and 114 perinatal outcomes. Reporters who had notified a case but not returned data were contacted by email 115 at one, two and three weeks after notification. This analysis reports characteristics and outcomes of 116 women who were hospitalized from 1st March 2020 to 31 st August 2020. Hospital admission was 117 defined as a hospital stay of 24 hours or longer for any cause, or admission of any duration to give 118 birth. Women were taken as confirmed SARS-CoV-2 if they were hospitalized during pregnancy or 119 within two days of giving birth and had a positive test during or within seven days of admission, or 120 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint they were symptomatic and had evidence of pneumonia on imaging which was typical of SARS-CoV-121 2. Women were excluded if they did not meet this case definition (n=294). 122 123 For each woman included, characteristics were described: body mass index, age, ethnicity, pregnancy 124 history and relevant pre-existing comorbidities, which were identified based on current NHS guidance 125 (Table S1 ) [11] ). Details of pregnancy outcome including admission to intensive care, evidence of 126 pneumonia on imaging, pre-eclampsia and mode and indication for birth were described as well as 127 infant outcomes including gestation at birth, stillbirth, live birth, admission to neonatal intensive care, 128 neonatal death and neonatal testing for SARS-CoV-2. Information on women who died, or who had 129 consequent stillbirths or neonatal deaths, was cross-checked with data from the MBRRACE-UK 130 collaboration, the organization responsible for maternal and perinatal death surveillance in the UK 131 [12] . If any women were identified through these sources who had not been identified for this study, 132 the nominated UKOSS clinician in the relevant hospital was contacted and asked to complete a data 133 collection form. 134

Women with any symptoms of SARS-CoV-2 (fever, cough, sore throat, breathlessness, headache, 136 fatigue, limb or joint pain, vomiting, rhinorrhea, diarrhea, anosmia, or SARS CoV-2 pneumonia on 137 imaging) that were admitted to hospital were compared to a historical comparison cohort of 138 uninfected women. The historical comparison cohort were obtained from a previous study of seasonal 139 influenza in pregnancy, where the two women giving birth immediately prior to any woman 140 hospitalized with confirmed influenza between 1 st November 2017 and 30 th October 2018 were 141 identified [13] . A historical cohort was used to ensure there was no possibility that comparison women 142 had asymptomatic or minimally symptomatic SARS-CoV-2 infection. Women who tested positive 143 during routine screening at the time of hospital admission with no symptoms at any point were also 144 compared to this historical comparison group. A sub-analysis compared women admitted to hospital 145 with symptomatic SARS-CoV-2 and women found to have asymptomatic SARS-CoV-2. 146 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. proportions are presented with 95% confidence intervals. Where data were missing, proportions are 165 presented out of cases known. Odds ratios (ORs) with 95% confidence intervals (CI) were estimated 166 using unconditional logistic regression. Exploratory analysis, using a hierarchical stepwise forward 167 selection procedure to add additional variables associated with the outcome in the univariable 168 analysis with subsequent likelihood ratio testing, was used to identify any potential confounders or 169 mediators for each analysis (P-value <0.05 considered significant for inclusion in the model). 170

Continuous variables were used in this exploratory analysis then categorized. Potential confounding 171 factors that were identified in a previous preliminary unpublished analysis [14] were included in the 172 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint multivariate model for the comparison of symptomatic SARS-CoV-2 to the historical comparison 173 group. Variables identified as significantly associated in the univariable analysis were adjusted. 174 175 A sensitivity analysis was undertaken for pre-existing medical problems that might have increased the 176 risk of infection with SARS-CoV-2 or resulting morbidity (e.g., diabetes) to explore if any were 177 independently associated with the outcome. In this national observational study, the study sample 178 size was governed by the disease incidence, thus no formal power calculation was carried out. The 179 most recently available (2018) national maternity data for the constituent countries of the United 180

Kingdom was used as the denominator to estimate the incidence of hospitalization with confirmed 181 SARS-CoV-2 infection in pregnancy. 182

Between 1 st March 2020 and 31 st August 2020 there was a total of 1148 hospitalized women with 185 confirmed SARS-CoV-2 infection in pregnancy in the UK, approximately two thirds of whom were 186 symptomatic (n=722, 63%). There were an estimated 364,830 maternities during this period, giving 187 an overall incidence of confirmed SARS-CoV-2 in women hospitalized in pregnancy of 3.1 per 1000 188 maternities (95% CI 3.0-3.3), an incidence of symptomatic SARS-CoV-2 of 2.0 per 1000 maternities 189 (95% CI 1.9-2.2) and an incidence of asymptomatic SAR-CoV-2 of 1.2 per 1000 maternities (95% CI 1.1-190 1.4). Most cases were in the first month of the pandemic as shown in Figure 1 , which also 191 demonstrates the greater proportion of symptomatic compared to asymptomatic cases at this time. 192

The majority (99%, n=1136) had SARS-CoV-2 confirmed on laboratory testing and 12 symptomatic 193 women (1%) were diagnosed on imaging alone. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. The most common time of diagnosis was during the third trimester (n=355, 50% of symptomatic 200 women and n=211, 50% of asymptomatic women). The primary reason for hospital admission was 201 known in 177 of 291 women admitted after universal screening was recommended. The most 202 common reason for asymptomatic women to be admitted to hospital was to give birth (68%, n=78), 203

whereas the primary reason that symptomatic women were admitted to hospital during the same 204 period was equally spread between admission for SARS-CoV-2, to give birth, and for other reasons 205 (30%, n=19, 37%, n=23 and 33% n=21 respectively). In symptomatic women, the majority had 206 experienced symptoms within two weeks of admission to hospital (n=645, 94% of 689 where date of 207 onset was known). 208 209 Compared to the historical comparison cohort without SARS-CoV-2, those hospitalized with 210 symptomatic SARS-CoV-2 were more likely to be overweight or obese ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. Nearly a quarter of women (22%, n=156) admitted with symptomatic SARS-CoV-2 had a relevant 217 medical comorbidity compared to 13% (n=90) of the historical comparison cohort (aOR 1.83, 95% CI 218 1.32-2.54). In the sensitivity analysis, there was some evidence that asthma and hypertension 219 specifically increased the risk of admission (Table S2 ). These risk factors were similar when comparing 220 the overall group of women admitted to hospital with SARS-CoV-2 (both symptomatic and 221 asymptomatic) to the historical comparison cohort of women without SARS-CoV-2 (Table S3) . 222 223 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. Table 2) . Women with asymptomatic SARS-CoV2 were also more likely to have gestational 232 diabetes compared to the historical comparison cohort (aOR 1.68, 95% CI 1.02-2.74), however raised 233 BMI and pre-existing medical co-morbidities were no longer associated (Table 2) . Therefore, there 234 were also differences between women with symptomatic SARS-CoV-2 and asymptomatic SARS-CoV-2 235 as identified in the sub-analysis (Table S4) . 236 237 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint (<1%) reported to have received extracorporeal membrane oxygenation (ECMO) ( Table 3 ). In those 247 women admitted for critical care there were five maternal deaths (8%); the majority of women 248 admitted to critical care with SARS-CoV-2 were discharged from hospital (n=56, 92%, Table S5 ). Whilst 249 most women admitted to critical care gave birth before 37 weeks of pregnancy (n=38, 64%), with 32% 250 (n=17) being born before 32 weeks, short term infant outcomes were good with 98% (n=60) being 251 liveborn (Table S5) . 252 253 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. Of the 722 women admitted to hospital with symptomatic SARS-CoV-2, 89% (n=640) had completed 261 their pregnancy at the time of analysis (Table 3 , two were missing further details and infant outcomes 262 so were excluded from the denominator). In total, 2% (n=16) of women with symptomatic SARS-CoV-263 2 had a pregnancy loss prior to 24 weeks'. Nearly half of women gave birth by cesarean section (n=314, 264 49%), with 64 (6%) being for maternal compromise secondary to SARS-CoV-2 (Table S6 ). This 265 represents approximately double the risk of cesarean section for women with symptomatic SARS-CoV-266 2 compared to the historical comparison cohort without SARS-CoV-2 (pre-labor cesarean aOR 2.58, 267 95% CI 1.88-3.55 and cesarean after labor onset aOR 2.72, 95% CI 1.79-3.86). Operative vaginal births 268 were also increased (aOR 2.14, 95% CI 1.42-3.24). Only 18 women received antiviral agents, two of 269 whom were recruited to the RECOVERY Trial [15] . The most commonly-used antiviral agent was 270 oseltamivir (n=11, 1%). Approximately 1 in 8 symptomatic women received steroids to enhance fetal 271 lung maturation (17%, n=120) and 1 in 5 symptomatic women had a preterm birth. The majority of 272 preterm births were iatrogenic and the risk of a woman with symptomatic SARS-CoV-2 having an 273 iatrogenic preterm birth was more than 10-fold higher compared to pregnant women without SARS-274 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. In comparison with women found to have asymptomatic SARS-CoV-2 on hospital admission, women 280 with symptomatic SARS-CoV-2 were more likely to have a cesarean birth (prelabor cesarean: 32% vs. 281 26%, OR 1.51, 95% CI 1.11-2.06 and cesarean after labor onset: 18% vs. 14%, OR 1.58, 95% CI 1.08-282 2.31) ( Table 4 ). Although the risk in the asymptomatic SARS-CoV-2 group was also increased compared 283 to the historical comparison cohort without SARS-CoV-2 ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint

Of the 634 infants born to mothers with symptomatic SARS-CoV-2, 627 (99%) were liveborn, 81% 296 (n=503) at term (Table 3 ). There were seven perinatal deaths in this group; five babies were stillborn 297 and two died in the neonatal period, none of whom had confirmed SARS-CoV-2. This represents a 298 perinatal mortality rate of 11 per 1000 births amongst hospitalized women with symptomatic SARS-299

CoV-2 (95% CI 4-23 per 1000). A total of 121 infants (19%) born to mothers with symptomatic SARS-300

CoV-2 were admitted to a neonatal unit compared to 5% (n=37) of infants in the historical comparison 301 cohort (aOR 3.08, 95% CI 1.99-4.77). Infants born to hospitalized mothers with symptomatic SARS-302

CoV-2 were more likely to be born at less than 37 weeks' and less than 32 weeks' of gestation 303 compared to babies born to the historical comparison cohort of mothers without SARS-CoV-2 (aOR 304 1.87, 95% CI 1.23-2.85 and aOR 3.98, 95% CI 1.48-10.70 respectively) ( Table 3 ). Infant outcomes were 305 similar when comparing the overall group of women admitted to hospital with SARS-CoV-2 (both 306 symptomatic and asymptomatic) to women without SARS-CoV2 (Table S7) . 307 308 More than one in four women that were symptomatic with SARS-CoV-2 were discharged prior to 309 giving birth and have now completed their pregnancy (n=206, 29%). In this group the majority went 310 on to have liveborn infants (n=204, 99%), at term (n=186, 90% vs n=314, 72% of those that gave birth 311 at the time of admission) with a lower proportion requiring neonatal unit admission compared to 312 those that were born at the time of admission (n=17, 8% vs. n=99, 23%). 313 314 There was no significant difference in the risk of stillbirth or neonatal death based on symptom status 315 or in asymptomatic SARS-CoV-2 compared to the historical comparison cohort. The risk of infant 316 admission to a neonatal unit was more than doubled in symptomatic compared to asymptomatic 317 women with SARS-CoV-2 on hospital admission (19% vs 9%; OR 1.93, 95% CI 1.34-2.78, Table 4 ). 318

Although the risk of neonatal unit admission was still increased when comparing women with 319 asymptomatic SARS-CoV-2 to the historical comparison cohort (9% vs. 5%, aOR 1.84, 95% CI 1.12-3.03, 320 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint Table 5 ). During this study period, universal screening was recommended for all babies born to 321 mothers with confirmed SARS-CoV-2 that were admitted to neonatal units for specialist care from 322

April 27 th 2020. Babies born to mothers with SARS-CoV-2 that were not admitted to neonatal units 323

were not routinely tested. Only 2% (n=23) of infants tested positive for SARS-CoV-2 RNA, 12 within 324 the first 12 hours of life. Five of the infants reported to have a positive test within 12 hours were 325 admitted to a neonatal unit; only 2 of these infants had confirmed infection on re-testing. Babies born 326 to women symptomatic of SARS-CoV-2 were more likely to be preterm compared to those born to 327 asymptomatic women (19% vs 9%, aOR 1.88, 95% CI 1.20-2.95, This national prospective cohort study has reported an incidence of symptomatic SARS-CoV-2 in 333 women hospitalized in pregnancy of 2.0 per 1000 maternities (95% CI 1.9-2.2) and an incidence of 334 asymptomatic SAR-CoV-2 in women hospitalized in pregnancy of 1.2 per 1000 maternities (95% CI 1.1-335 1.4). Compared to hospitalized pregnant women without SARS-CoV-2, hospitalized women with 336 symptomatic SARS-CoV-2 were more likely to be overweight or obese, to be of Black, Asian or Other 337 minority ethnic group, and to have a relevant medical comorbidity including asthma and hypertension. 338

The characteristics associated with asymptomatic SARS-CoV2 on hospital admission were Black, Asian 339 or Other minority ethnicity and gestational diabetes. Hospitalized pregnant women with symptomatic 340 SARS-CoV-2 were more likely to be admitted to intensive care. They were more likely to have a 341 cesarean or an operative vaginal birth, regardless of their symptom status, although the risk was 342 greatest in those symptomatic for SARS-CoV-2. Hospitalized women with SARS-CoV-2 were more likely 343 to have a preterm birth. This was driven by increased iatrogenic birth in women that were 344 symptomatic of SARS-CoV-2, as risk of preterm birth in asymptomatic women was not increased. 345

Babies born to women with SARS-CoV-2 were more likely to be admitted to a neonatal unit, regardless 346 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint of the mother's symptom status. There was no significant increase in stillbirth and neonatal deaths in 347 hospitalized pregnant women with SARS-CoV-2 compared to those without SARS-CoV-2, or between 348 those with symptoms and those that were asymptomatic but numbers in these groups were small. 349 350 This established method of nationwide, prospective case identification allowed rapid inception of 351 reporting of population-based data, which has added an unbiased confirmation to existing reports of 352 the characteristics and outcomes for SARS-CoV-2 in women hospitalized in pregnancy. As UKOSS is 353 the only national research platform for obstetrics in the UK, all other reports on this outcome during 354 this time frame will be a subset of these data, including our initial publication of the first six weeks of 355 the pandemic [3] . The comparison to a historical unexposed group without SARS-CoV-2 allowed 356 conclusions to be drawn about the characteristics associated with hospitalization. However, we were 357 unable to evaluate the outcomes in women with mild symptoms who were not admitted to hospital, 358 nor the incidence and outcomes of asymptomatic infection in pregnant women not presenting to 359 hospital for another cause. This study was undertaken in a high resource setting with universal health 360 care at the point of access, therefore results are generalizable to similar settings. 361

The sub-analysis of women by symptom status is a strength of this study. We have shown that since 363 universal testing was recommended nationally, 64% of women admitted to hospital with confirmed 364 SARS-CoV-2 were asymptomatic. To the best of our knowledge this is the first population-based study 365 to report on symptom status in pregnancy. This analysis is important because women requiring 366 hospital admission are by nature more likely to be at increased risk of adverse pregnancy outcome. 367

For example, 3% (n=31) of hospitalized pregnant women with SARS-CoV-2 had a pregnancy loss 368 compared to <1% (n=2) of those without SARS-CoV-2, but this could be a result of increased testing 369 on admission in women presenting to hospital with symptoms of pregnancy loss as opposed to an 370 effect of SARS-CoV-2 itself. This is supported by the finding of similar proportions of women with 371 pregnancy loss in the sub-analysis by symptom status. The small increase in the proportion of 372 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi. org/10.1101 org/10. /2021 stillbirths in women with SARS-CoV-2 compared to those without SARS-CoV-2 may also be a result of 373 this measurement bias. However, it is a limitation that despite national guidance, practice around 374 initiation of universal screening will have varied between hospitals depending on testing capacity with 375 some initiating screening earlier or later than recommended. This will have influenced the proportion 376 of asymptomatic women detected throughout this study. 377

We have confirmed that pregnant women hospitalized with SARS-CoV-2 were more likely to be Black, 379

Asian or Other minority ethnicity, irrespective of symptom status, age, BMI and medical comorbidities. 380

In the non-pregnant population, a recent systematic review has demonstrated that Black and Asian 381 ethnic groups are more likely to be infected with SARS-CoV-2 compared to those of White ethnicity 382 [16] . This suggests that the disproportionate impact could be attributable to increased infection in 383 these ethnic groups. However, disparities in maternal mortality between ethnic groups are well known 384 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint further research is required. In this study we have identified that very few pregnant women (2%) were 399 treated with anti-viral medications, much lower than in some other high resource countries such as 400

Italy where nearly a quarter of women (23%) received treatment with anti-viral agents [22] . Evidence 401 about pharmacological management in the general population is improving [15] . We have identified 402 risk factors that increase the likelihood of hospitalization and symptoms of SARS-CoV-2 and therefore 403 potentially identify those who women may benefit most from evidence-based treatment. The RCOG 404 recommends that clinicians should consider the use of medications which have been shown to be 405 beneficial and that pregnant women should be offered inclusion in trials of therapy to reduce the 406 severity of SARS-CoV-2 [20] . 407

We have demonstrated that hospitalization with SARS-CoV-2 is associated with increased risk of 409 cesarean section, irrespective of symptom status. This supports recent systematic reviews, which have 410 reported up to 60% of pregnant women with SARS-CoV-2 had a cesarean birth [2, 23] . We also provide 411 clear data on the indication for interventional birth, the majority of which were unrelated to SARS-412

CoV-2. The finding that cesareans are increased irrespective of symptom status suggests that some of 413 the overall increased risk is a result of measurement bias, as women with pregnancy complications 414 requiring cesarean birth are more likely to present to hospital and be screened and delivered than the 415 comparison population. However, changes in maternity practice may also contribute to this increase 416 and this warrants further investigation, as it has implications for informed decision-making, future 417 pregnancies and resource availability in both high and low-income settings. 418 419 Nearly one in five (n=120) infants of hospitalized mothers with SARS-CoV2 were born preterm and the 420 majority of these preterm infants required neonatal care (n=98, 63%). However, this was driven by 421 iatrogenic preterm birth and there was a suggestion that spontaneous preterm birth was reduced. A 422 number of other studies undertaken in high-resource settings have also reported a significant 423 reduction in preterm births and hypothesized that this was due to beneficial effects of the pandemic 424 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint control measures such as handwashing and social distancing reducing infections, reduced air pollution 425 and greater physical rest [24, 25] . Further research is required to determine the impact of social and 426 behavioral changes in differing risk groups and their impact on maternity outcomes in this pandemic. 427

Additionally, the high rates of iatrogenic preterm birth and neonatal unit admission due to prematurity 428 continue to suggest that the indirect effects of SARS-CoV-2 on delivery of maternity care are important 429 and will continue to be so, especially in the absence of vaccine use in pregnant women [26] . Our data 430 suggest that clinicians should be reassured that women with mild SARS-CoV-2 can be discharged from 431 hospital to continue their pregnancy safely. 432 433

This national study has demonstrated that raised BMI, Black, Asian or Other minority ethnicity and 435 relevant medical co-morbidities are associated with hospitalization with symptomatic SARS-CoV-2. 436

These groups should be considered for inclusion and prioritization when testing SARS-CoV-2 vaccine 437 efficacy and safety. Risks could be minimized where possible through pre-pregnancy optimization of 438 weight and medical co-morbidities. Further research is required to determine why women of Black, 439

Asian and Other minority ethnicity are disproportionately affected and how to minimize the impact of 440 this through care provision. Overall, just under one in 10 women admitted to hospital with symptoms 441 of SARS-CoV-2 in pregnancy required critical care. Outcomes in this group are predominantly good, 442 but women should be treated with medications known to be effective, to ensure their outcomes 443 improve in line with the general population. The proportion of cesarean births and iatrogenic preterm 444 birth is high which provides clear evidence of the indirect impact of SARS-CoV-2 on maternity care in 445 a high-income setting. This needs to be taken into account in guidance as the pandemic continues and 446 as SARS-CoV-2 moves to become an endemic infection, in order to prevent immediate complications 447 such as neonatal prematurity and long-term complications associated with over-intervention in care. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Supporting Information Captions 562 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249195 doi: medRxiv preprint

World Health Organisation

World Health Organisation

Clinical 465 manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 466 2019 in pregnancy: living systematic review and meta-analysis

Characteristics and 469 outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in 470 UK: national population based cohort study

Principles for the testing and triage 473 of women seeking maternity care in hospital settings, during the COVID-19 pandemic; A 474 supplementary framework for maternity healthcare professionals. Royal College of 475 Obstetricians and Gynaecologists

Universal screening for SARS-CoV-2 in pregnant women at term admitted to an East London 478 maternity unit. European journal of obstetrics, gynecology, and reproductive biology

Covid-19: Nine in 10 pregnant women with infection when admitted for 482 delivery are asymptomatic, small study finds

Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in 486

a prospective cohort study

Universal 489 SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care 490

System for rare disorders of pregnancy

COVID-19 London: National Institute for Health Research

Who's at higher risk from coronavirus: National Health 500 Service

Saving Lives, Improving Mothers' Care -Lessons learned to 505 inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths 506 and Morbidity 2014-16

UK Obstetric Surveillance System. Seasonal Influenza in Pregnancy

Characteristics and 510 outcomes of pregnant women hospitalised with confirmed SARS-CoV-2 infection in the UK: a 511 national cohort study using the UK Obstetric Surveillance System (UKOSS)

Nuffied Department of Population Health

Ethnicity and clinical 518 outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine

Socio-demographic 521 heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and 522 household size: Results from an observational cohort study

Covid-19: Deprived areas have the highest death rates in England and 525

Office for National Statistics United Kingdom Government. Coronavirus (COVID-19) 527 related deaths by occupation, England and Wales: deaths registered up to and including 20 528